Drug Type Small molecule drug |
Synonyms 7-chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide, CDP, Chloradiazepoxide + [9] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (24 Feb 1960), |
Regulation- |
Molecular FormulaC16H14ClN3O |
InChIKeyANTSCNMPPGJYLG-UHFFFAOYSA-N |
CAS Registry58-25-3 |
Start Date20 Nov 2024 |
Sponsor / Collaborator |
Start Date20 Mar 2021 |
Sponsor / Collaborator |
Start Date15 Jul 2020 |
Sponsor / Collaborator- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00267 | Chlordiazepoxide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Epilepsy | China | 01 Jan 1981 | |
Sleep Initiation and Maintenance Disorders | China | 01 Jan 1981 | |
Mood Disorders | Japan | 01 Jun 1961 | |
Muscle Spasticity | Japan | 14 Mar 1961 | |
Depressive Disorder | Japan | 28 Feb 1961 | |
Neurotic Disorders | Japan | 28 Feb 1961 | |
Anxiety Disorders | United States | 24 Feb 1960 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |